do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment Working mechanisms of GLP-1, GLP-1

Back Madsen, OD, Karlsen, C, Blume, N, et al (1995) 'Transplantable glucagonomas derived from pluripotent rat islet tumor tissue cause severe anorexia and adipsia', Scandinavian Journal of Clinical and Laboratory Investigation Supplement , 220, 27-35

(26) GLP-1 agonists also demonstrated consistent reductions in lower limb amputation risk across subgroups, including those with peripheral arterial disease (PAD) and patients on antihypertensive therapy

Zhang L, Li C, Zhu Q, Li N, Zhou H

Research continues into additional applications

Van Harken DR, Dixon CW, Heimberg M

These variables, which were selected because they are likely to affect treatment outcomes, encompassed both demographic factors (region, sex, age at index date) and clinical history (baseline HbA1c, baseline weight, CVD in the past 365 day [coronary heart disease, cerebrovascular disease, peripheral vascular disease or heart failure], CharlsonDeyo risk index score), as well as index year, insurance type and previous receipt of oral antidiabetic medications